May. 24 at 1:53 PM
$RCKT So if I'm reading this right they've got one approved drug that might max out revenue at 1/4 to 1/2 of annual cash burn. One other that had a death, so while promising, could be completely shut down by another adverse event, and a couple of others years in the offing. Explain again why this should be trading substantially higher? Citing value to cash on hand is weak as all the cash on hand will be burned in 2 years, and if there are any more holds on Danon approval, the company will likely need to dilute next year.
